According to data from a recently released late-stage trial, treatment with Bristol Myers Squibb’s immunotherapies, Opdivo and Yervoy, had better outcomes for patients than the patients who did not get the drugs before node removal procedures.
The study of 423 patients with stage 3 melanoma found around 58% of patients in the treatment arm had a complete pathologic response, meaning there was no sign of cancer in the removed lymph nodes, and they did not receive additional treatment.